



Press release
7 April, 2020

Kringle Pharma Additionally Raises 740 Million Japanese Yen Toward Commercialization of Recombinant Human HGF Drug

Kringle Pharma, Inc. (Head office located in Ibaraki, Osaka; President & CEO, Kiichi Adachi; “KRINGLE”) announces that the company has additionally raised funds amounting to 740 million Japanese yen, after the first closing of 950 million Japanese yen at the end of February 2020. As a result, the total amount of this financing round reaches 1,690 million Japanese yen (approximately \$15.5 million US dollars). The companies participating in this extension round in KRINGLE include new investors such as *Osaka University Venture Capital Co., Ltd.*, *Chishima Real Estate Co., Ltd.*, *Resona Capital Co., Ltd.*, *MSF Capital Partners G. K. (A subsidiary of Miraca Holdings, Inc.)*, *The Nanto Bank, Ltd. / Venture Labo Investment Co., Ltd.*, *Yitu Capital*, *HT Capital*, and *OKB Capital Co., Ltd.*

Hepatocyte growth factor (HGF) is considered an intrinsic repair and regeneration factor for various tissues and organs, and is thought to have significant potential as an innovative medicine for many intractable diseases. KRINGLE has been deeply engaged in the clinical development of recombinant human HGF (rhHGF) for acute spinal cord injury and amyotrophic lateral sclerosis (ALS). Funds raised by this round will be used for the preparation and initiation of a seminal Phase III clinical study in acute spinal cord injury, GMP production of rhHGF and its process validation in anticipation of a new drug application in Japan.

About Kringle Pharma, Inc. <https://www.kringle-pharma.com/en/>

Kringle Pharma is a clinical-stage biopharmaceutical company established in December 2001 to develop novel biologics based on HGF. Currently, Kringle’s clinical programs with rhHGF are: 1) Phase I/II DBT in acute spinal cord injury (completed), 2) investigator-initiated Phase II DBT in ALS (ongoing), 3) Phase I in acute kidney injury (completed), and 4) investigator-initiated Phase I/II in vocal fold scar (completed). Kringle’s mission is to contribute to societal and global health through the continued research, development and commercialization of rhHGF for patients suffering from incurable diseases.

For more information, please contact:

Yutaka Matsuura, C.P.A.

Director of Corporate Planning Management, Member of the Board

Kringle Pharma, Inc.

☎ +81-72-641-8739

✉ kpinfo@kringle-pharma.com